Genetic inactivation of ADAMTS15 metalloprotease in human colorectal cancer

Cancer Research

Volumn 69, Issue 11, 2009, Pages 4926-4934

  Viloria, Cristina G ^a   Obaya, Alvaro J ^b   Moncada Pazos, Angela ^a   Llamazares, María ^a   Astudillo, Aurora ^c   Capellá, Gabriel ^d   Cal, Santiago ^a   López Otín, Carlos ^a  

^a DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^b UNIVERSIDAD DE OVIEDO   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^d BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

METALLOPROTEINASE; PROTEIN ADAMTS15; UNCLASSIFIED DRUG;

ADAMTS15 GENE; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; GENE INACTIVATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; SEQUENCE ALIGNMENT; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

EID: 66349114309     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4155     Document Type: Article

References (35)

1. Lopez-Otin C, Bond JS. Proteases: multifunctional enzymes in life and disease. J Biol Chem 2008;283:30433-30437
2. Jin H, Wang X, Ying J, et al. Epigenetic identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently silenced in esophageal, nasopharyngeal and multiple other carcinomas. Oncogene 2007;26:7490-7498 (Pubitemid 350158717)
3. Freije JM, Balbin M, Pendas AM, Sanchez LM, Puente XS, Lopez-Otin C. Matrix metalloproteinases and tumor progression. Adv Exp Med Biol 2003;532:91-107. (Pubitemid 37176782)
4. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-2392 (Pubitemid 34270240)
5. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002;2:657-672 (Pubitemid 37328917)
6. Balbin M, Fueyo A, Tester AM, et al. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet 2003;35:252-257 (Pubitemid 37363179)
7. Lopez-Otin C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer 2007;7:800-808 (Pubitemid 47463671)
8. Porter S, Clark IM, Kevorkian L, Edwards DR. The ADAMTS metalloproteinases. Biochem J 2005;386:15-27.
9. Apte SS. A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motifs: the ADAMTS family. Int J Biochem Cell Biol 2004;36:981-985 (Pubitemid 38501549)
10. Rocks N, Paulissen G, El Hour M, et al. Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie 2008;90:369-379
11. Tang BL. ADAMTS: a novel family of extracellular matrix proteases. Int J Biochem Cell Biol 2001;33:33-44. (Pubitemid 32146465)
12. Kuno K, Kanada N, Nakashima E, Fujiki F, Ichimura F, Matsushima K. Molecular cloning of a gene encoding a new type of metalloproteinase-disintegrin family protein with thrombospondin motifs as an inflammation associated gene. J Biol Chem 1997;272:556-562 (Pubitemid 27021194)
13. Vazquez F, Hastings G, Ortega MA, et al. METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. J Biol Chem 1999;274:23349-23357 (Pubitemid 29388089)
14. Dunn JR, Reed JE, du Plessis DG, et al. Expression of ADAMTS-8, a secreted protease with antiangiogenic properties, is downregulated in brain tumours. Br J Cancer 2006;94:1186-1193
15. Llamazares M, Obaya AJ, Moncada-Pazos A, et al. The ADAMTS12 metalloproteinase exhibits anti-tumorigenic properties through modulation of the Ras-dependent ERK signalling pathway. J Cell Sci 2007;120:3544-3552 (Pubitemid 350120947)
16. Lind GE, Kleivi K, Meling GI, et al. ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis. Cell Oncol 2006;28:259-272
17. Lo PH, Leung AC, Kwok CY, et al. Identification of a tumor suppressive critical region mapping to 3p14.2 in esophageal squamous cell carcinoma and studies of a candidate tumor suppressor gene, ADAMTS9. Oncogene 2007;26:148-157 (Pubitemid 46067340)
18. Jin H, Wang X, Ying J, et al. Epigenetic identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently silenced in esophageal, nasopharyngeal and multiple other carcinomas. Oncogene 2007;26:7490-7498 (Pubitemid 350158717)
19. Porter S, Span PN, Sweep FC, et al. ADAMTS8 and ADAMTS15 expression predicts survival in human breast carcinoma. Int J Cancer 2006;118:1241-1247 (Pubitemid 43185612)
20. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314:268-274 (Pubitemid 44571966)
21. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108-1113 (Pubitemid 350134889)
22. Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 2003;31:3812-3814 (Pubitemid 37442253)
23. Cal S, Obaya AJ, Llamazares M, Garabaya C, Quesada V, Lopez-Otin C. Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains. Gene 2002;283:49-62. (Pubitemid 34178509)
24. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 1989;77:51-59 (Pubitemid 19125653)
25. Suga A, Hikasa H, Taira M. Xenopus ADAMTS1 negatively modulates FGF signaling independent of its metalloprotease activity. Dev Biol 2006;295:26-39. (Pubitemid 44041323)
26. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 2006;66:8319-8326 (Pubitemid 44449137)
27. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26:3291-3310
28. Zhang YW, Su Y, Volpert OV, Vande Woude GF. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci U S A 2003;100:12718-12723 (Pubitemid 37339965)
29. Ren B, Yee KO, Lawler J, Khosravi-Far R. Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta 2006;1765:178-188
30. Kuno K, Bannai K, Hakozaki M, Matsushima K, Hirose K. The carboxyl-terminal half region of ADAMTS-1 suppresses both tumorigenicity and experimental tumor metastatic potential. Biochem Biophys Res Commun 2004;319:1327-1333 (Pubitemid 38759556)
31. Liu YJ, Xu Y, Yu Q. Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively. Oncogene 2006;25:2452-2467
32. Rashid A, Shen L, Morris JS, Issa JP, Hamilton SR. CpG island methylation in colorectal adenomas. Am J Pathol 2001;159:1129-1135 (Pubitemid 32847204)
33. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-1806
34. Connolly KC, Gabra H, Millwater CJ, et al. Identification of a region of frequent loss of heterozygosity at 11q24 in colorectal cancer. Cancer Res 1999;59:2806-2809 (Pubitemid 29283113)
35. Lopez-Otin C, Overall CM. Protease degradomics: a new challenge for proteomics. Nat Rev Mol Cell Biol 2002;3:509-519 (Pubitemid 34733432)